According to a new research report “Systemic Lupus Erythematosus (SLE) Therapeutics – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, SLE therapeutics currently exhibits a proliferating pipeline with 15+ therapeutic candidates.
SLE Therapeutics Pipeline Insights
Systemic lupus erythematosus (SLE) is a chronic disease that causes inflammation of cartilage and blood vessels. Pain and swelling in joints, sensitivity to sun, unexplained fever, joints and muscle pain, mouth ulcers, swollen glands, and others are some common symptoms of the disease. Additionally, kidneys, lungs, heart, and others can also get affected by SLE. The diagnosis of SLE is little difficult as it requires multiple tests and constant analysis. Anticardiolipin antibody test, antinuclear antibody (ANA) test, blood chemistries, complete blood count (CBC), urinalysis, and the erythrocyte sedimentation rate (ESR) are some tests to diagnose the disease.
The treatment for the disorder includes anti-inflammatory medications for joint pain and stiffness, steroid creams for rashes, corticosteroids to minimize the immune response, and antimalarial drugs for skin and joint problems. Whereas, Benlysta (GlaxoSmithKline plc) is the only approved drug available for the treatment of SLE.
Insights into Pipeline Segments
According to the research, most of the drug candidates being developed for SLE are administered topically. It is observed that this route of medication is most effective method of treatment. It has been found that topical route of administration is easy to use, non-invasive, and ensures high level of patient satisfaction.
Positive Clinical Trial Results are Expected to Drive the SLE Therapeutics Pipeline Advancements
Companies that are developing therapeutics for SLE have shown positive clinical results in the various phases of drug development. For instance, in March 2018, Ablynx announced topline results of vobarilizumab phase II trials. Treatment-related serious adverse events were reported in 2.0% of all vobarilizumab treated patients as compared to 6.5% in patients administered with placebo. The percentage of patients experiencing a serious infection was also lower in the vobarilizumab arms compared to the placebo arm (2.8% versus 6.5%). Treatment-emergent adverse events that led to study drug discontinuation were reported in 12.4% of all vobarilizumab treated patients.
Global Market of SLE Therapeutics is Expected to Increase Statistically in the next 10 years
Benlysta is the only marketed therapeutic product available for SLE. Therefore, with the emergence of late- and mid-stage pipeline products in the market, the overall SLE therapeutics market is expected to grow significantly in the upcoming years.
Technological Advancements Play a Pivotal Role in the SLE Therapeutics Development
Pharmaceutical companies are tending to develop various strategies to enhance the therapeutic pipeline of SLE. For instance, Ablynx is developing vobarilizumab for the treatment of vobarilizumab with the help of its proprietary Nanobody technology.
Takeda Pharmaceutical Company Limited, Anthera Pharmaceuticals Inc., Genentech Inc., UCB Biopharma SPRL, Merck & Co. Inc., Ablynx, and GlaxoSmithKline plc are some of the prominent players for developing drugs and therapies for SLE.
Browse report overview with detailed TOC on "Systemic Lupus Erythematosus (SLE) Therapeutics – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments" at:https://www.pharmaproff.com/report/systemic-lupus-erythematosus-pipeline-analysis
SLE Therapeutics Pipeline Analysis
The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of SLE. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the SLE therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in the report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to SLE.